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Conventional antidepressants have several important limitations, including a lack of
direct effects on negative self-schema, which is at the core of Beck’s cognitive theory
of depression. Based on previous studies showing a positive effect of ketamine
on negative cognition, we compared reductions in negative self-schema between
responders and non-responders to a single infusion of ketamine. In an open-label
study, 26 participants with treatment-resistant depression received 0.5 mg/kg ketamine
via infusion. Depression symptoms were assessed at baseline, 24 h, and 7 days
after treatment with Montgomery-Åsberg Depression Rating Scale (MADRS) and Beck
Depression Inventory (BDI-II). Nine of the 26 participants fulfilled response criteria after
24 h. Of these, eight still fulfilled response criteria after 7 days. Response was defined as
a reduction in MADRS total score of 50% or more. Responders improved significantly
more than non-responders both 24 h and 7 days after ketamine treatment on the
following BDI-II items: item 1 (“Sadness”), item 7 (“Self-Dislike”), and item 8 (“Self-
Criticalness”). These results suggest an important therapeutic effect of ketamine on
negative self-schema, which is a fundamental cognitive aspect of depression. This effect
is unique and might be associated with ketamine’s profound effects on neuroplasticity.
Small sample size and lack of a placebo control group are the major limitations of
this study.
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INTRODUCTION
Conventional antidepressants are thought to produce their impact on clinical symptoms by
increasing monoamine concentration in the synaptic cleft. These drugs continue to be the first-
line choice in the pharmacotherapy of depression. However, they have major shortcomings, such as
a delayed onset of action and a high rate of non-response.
The discovery of ketamine as a rapid antidepressant has caused a paradigm shift in depression
research and treatment (Krystal et al., 2019). A single dose of ketamine was shown to produce
rapid, profound and surprisingly durable antidepressant effects (Berman et al., 2000). Importantly,
studies demonstrated that ketamine was effective in antidepressant non-responders (Zarate et al.,
2006). Aggregate analysis of placebo-controlled trials suggested that ketamine has a specific profile
of action (Ballard et al., 2018). Overall, ketamine improved depressed mood, negative cognition,
anhedonia, and suicidal thoughts better than tension, reduced appetite, and impaired sleep.
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In this study, we used data from uncontrolled, naturalistic
treatment of severely depressed patients with a single infusion
of ketamine. We used the Montgomery-Åsberg Depression
Rating Scale (MADRS) to evaluate response. Participants were
categorized as responders if they displayed an improvement of
50% or more of their baseline MADRS score after 24 h, and as
non-responders otherwise. In a next step, we analyzed the profile
of symptom improvement after ketamine treatment. To this end,
we examined differences in symptom improvements between
responders and non-responders in Beck Depression Inventory
(BDI-II) 24 h and 7 days after treatment.
METHODS
Study Sample
All participants provided informed consent prior to the ketamine
treatment. The retrospective exploratory analysis of clinically
assessed data was approved by the local ethics committee Bern
(Kantonale Ethikkommission Bern). The study was carried out in
accordance with the guidelines of the Swiss Academy of Medical
Sciences (SAMW) and applicable Swiss law.
We included the entire cohort of 26 persons that received
ketamine for treatment-resistant depression in a tertiary
treatment center of the University Hospital of Psychiatry and
Psychotherapy, University of Bern, Switzerland. Inclusion criteria
comprised a diagnosis of a severe mood disorder following ICD-
10 criteria, treatment resistance (non-response to at least three
different treatments), and age greater than 18 years. We excluded
participants fulfilling the following criteria: psychotic symptoms
or full manic episodes in the past, misuse of ketamine or other
illegal substances, ECG abnormalities (higher grade blockages
and pre-existing QT/QTc extensions), any heart disease, acutely
increased risk of suicide 14 days before treatment, any acute
somatic disease, history of severe somatic disease, history of
epileptic seizures, known ketamine hypersensitivity, pregnancy,
thyroid gland disorders, severe cognitive deficits, neuropathic
pain, glaucoma, anticoagulants, any coagulation disorder, and
any contraindications against intravenous applications.
The clinical data collected include the following demographic
and clinical characteristics: age, sex, body mass index (BMI),
age at first episode, current episode duration, past substance
abuse, past alcohol use disorder, and family history of
psychiatric disorders.
Ketamine Treatment
Participants received 0.5 mg/kg ketamine via infusion over
40 min. Of 26 subjects, 18 received only one ketamine treatment,
six received two ketamine infusions, one received three ketamine
administrations, and one received a total of five ketamine
infusions. Multiple ketamine administrations were separated by
periods of 4 to 42 weeks. Here, we present only findings from the
first ketamine treatment.
Clinical Response
Clinicians assessed depression symptoms using MADRS
(Montgomery and Asberg, 1979) at three time points: at baseline,
TABLE 1 | Clinical characteristics.
Sample characteristic Descriptive statistics
Sample size 261
Age 48.5 ± 2.818 (24–73)2
Age of first episode 27.923 ± 2.69 (6–64)2
Current episode duration 3.078 ± 1.012 (0.038–23)2
Body mass index 25.488 ± 0.917 (19.152–40.152)2
MADRS score at baseline 26.846 ± 1.194 (11–36)2
Female subjects 131
Subjects with Major Depressive Disorder 231
Subjects with Bipolar Disorder 31
Family history of psychiatric disorders 171
History of alcohol abuse 21
1 Indicates number of participants (count); 2 Indicates mean ± standard error of the
mean with range in parentheses: (minimum–maximum).
24 h after treatment, and 7 days after treatment. In addition,
at each time point, participants filled out Beck Depression
Inventory (BDI-II) (Beck et al., 1996). We quantified treatment
outcome after 24 h as percent MADRS total score change from
baseline. We categorized participants as responders if they
displayed an improvement of 50% or more of their baseline
MADRS score after 24 h, and as non-responders otherwise.
Statistical Analysis
First, we tested normality for each quantified variable with
Shapiro–Wilk test, assuming that p-values < 0.05, uncorrected
for multiple comparisons, reflect significant deviations from
normal distribution. Second, we tested the effect of ketamine
on MADRS total score with a repeated-measures analysis
of variance (ANOVA). We analyzed the correlation between
MADRS total score change 24 h and 7 days after ketamine
treatment and age, age of first episode, and BMI. We ran
one-tailed tests for the correlation between BMI and percent
MADRS total score improvement, based on previous reports.
Next, we classified all subjects as responders versus non-
responders according to a MADRS total score improvement
of 50% or more after 24 h. Finally, for each BDI-II item
we compared score changes from baseline to 24 h and
7 days after treatment in responders to score changes in non-
responders. To this end, we used Welch tests and Mann-Whitney
tests (one-tailed, expecting larger differences in responders,
uncorrected for multiple testing). We supplemented statistical
analyses with measures of effect size. For all inferential and
descriptive statistics, we reported exact values rounded to
the third decimal.
We carried out all statistical analyses in R (R Core Team.
R Foundation for Statistical Computing, Vienna, Austria)1.
In addition to core R functionalities, we used package “ez”
for repeated measures analysis of variance, package “effsize”
to calculate effect sizes, and packages “lattice,” “latticeExtra,”
“gridExtra,” and “ggplot2” to plot figures.
1https://www.R-project.org/
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RESULTS
Study Sample
Table 1 presents a summary of demographic and clinical
characteristics. We tested 26 participants (13 female) with a mean
age of 48.5 years (range: 24–73). Mean age of first episode was
27.923 years (range: 6–64). Mean MADRS total score at baseline
was 26.846 (range: 11–36). Twenty-two participants fulfilled
diagnostic criteria for recurrent major depressive disorder (F33).
Three subjects met diagnostic criteria for bipolar disorder with
a current depressive episode (F31.3), and one participant was
diagnosed with another depressive episode (F32.8).
Data Distribution
Shapiro-Wilk tests did not indicate significant deviations from
normality for MADRS and BDI-II total scores, MADRS and BDI-
II total score changes from baseline to 24 h after treatment, age,
and age of first episode (p-values > 0.05, uncorrected for multiple
comparisons, Supplementary Tables S1–S3). In contrast, current
episode duration, MADRS and BDI-II percent total score changes
from baseline to 7 days after treatment, MADRS and BDI-II
item scores at each of the three timepoints, and BMI deviated
significantly from normality (p-values < 0.05, uncorrected for
multiple comparisons, Supplementary Tables S1–S3). Therefore,
in the following, we supplemented the results of parametric tests
with non-parametric procedures, to exclude statistical artifacts,
caused by skewed distributions, in parametric tests.
Symptom Improvements After Ketamine
Treatment as Measured With MADRS
Mean MADRS total score decreased from 26.8 at baseline (range:
11–36, n = 26) to 17.5 at 24 h (range: 0–35, n = 26) and 18.6
at 7 days (range: 0–34, n = 25) after ketamine treatment. These
changes were statistically significant (Supplementary Table S4
and Supplementary Figure S1). Post hoc t-tests and Wilcoxon
signed-rank tests showed significant decreases from baseline to
24 h and 7 days after treatment (Supplementary Tables S5, S6).
We found no significant difference between MADRS total scores
24 h and 7 days after ketamine treatment, indicating a sustained
improvement over a week (Supplementary Tables S5, S6).
We found considerable interindividual variability in the
response to ketamine treatment. MADRS total score changes
varied from a 3.0% increase to a complete remission (reduction
of 100%) after 7 days. Nine of the 26 participants fulfilled
response criteria after 24 h, corresponding to a fraction of 34.6%.
Importantly, response to ketamine was stable over time: eight of
the nine responders still fulfilled response criteria after 7 days
(88.9%). Only one out of nine responders at 24 h post-treatment
did not meet response criteria after 7 days (11.1%), and only
1 out of 16 non-responders after 24 h was categorized as a
responder 7 days after ketamine treatment (6.3%). MADRS total
score percent change from baseline to 24 h after treatment
closely corresponded to MADRS total score percent change
from baseline to 7 days after treatment (Pearson’s r = 0.832,
p < 0.001, two-tailed; Spearman’s rho = 0.862, p < 0.001,
two-tailed; n = 25, one non-responder at 24 h could not be
tested 7 days after ketamine treatment because she left the
treatment center).
Correlation analyses indicated that higher BMI corresponded
to higher MADRS percent total score improvement after 24 h and
7 days (Supplementary Tables S7, S8).
MADRS Item Profile of Symptom
Improvements After Ketamine Treatment
Parametric explorative analyses revealed a rather unspecific effect
of ketamine on MADRS scores at the item level (Supplementary
Tables S9, S10). Item scores decreased significantly for all
MADRS items after 24 h, except for item 5 (“Reduced Appetite”)
(p = 0.096, two-tailed, uncorrected for multiple comparison).
Comparisons Between Responders and
Non-responders
Responders and non-responders did not differ significantly in
their total MADRS and BDI-II scores at baseline (Supplementary
Table S11). Comparisons at the item level indicated higher
scores in non-responders in item 13 (“Indecisiveness,” p = 0.26,
two-tailed, uncorrected for multiple comparisons) and item 19
(“Concentration,” p = 0.49, two-tailed, uncorrected for multiple
comparisons). Non-parametric comparisons corroborated the
difference in item 13 and suggested a trend for item 19
(Supplementary Table S11).
Twenty-four hours after ketamine treatment responders
showed better improvements than non-responders on the
following BDI-II items: sadness, pessimistic thoughts, loss
of pleasure, self-dislike, self-criticalness, suicidal thoughts,
increased crying, loss of energy, and changes in sleep pattern
(Figure 1 and Supplementary Table S12). Non-parametric tests
confirmed this item response profile (Supplementary Table S13).
Seven days after ketamine treatment responders still displayed
better improvement than non-responders in the items sadness,
guilty, self-dislike, self-criticalness, and worthlessness (Figure 1
and Supplementary Table S12). Non-parametric tests confirmed
these results and showed a better symptom improvement in
responders in three further items: failure, agitation, and loss of
energy (Supplementary Table S13). Thus, overall, responders
improved significantly more than non-responders both 24 h
and 7 days after ketamine treatment on the following BDI-
II items: item 1 (“Sadness”), item 7 (“Self-Dislike”), and
item 8 (“Self-Criticalness”) (Figure 1; p-values < 0.05, one-
tailed, uncorrected for multiple comparisons, Supplementary
Table S12). Mean score change from baseline to 24 h after
ketamine treatment for non-responders and responders was,
respectively, −0.47 and −1.333 for item 1 (“Sadness”), −0.176
and −1.111 for item 7 (“Self-Dislike”), −0.294 and −1 for
item 8 (“Self-Criticalness”) (negative values indicating a score
decrease). Mean score change from baseline to 7 days after
ketamine treatment for non-responders and responders was,
respectively, −0.188 and −1.111 for item 1 (“Sadness”), 0.125
and −0.667 for item 7 (“Self-Dislike”), −0.125 and −0.889
for item 8 (“Self-Criticalness”) (negative values indicating a
score decrease).
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FIGURE 1 | The figure shows effect sizes for comparisons between
responders and non-responders. Panel (A) shows BDI-II item score changes
from baseline to 24 h after ketamine treatment. Panel (B) shows BDI-II item
score changes from baseline to 7 days after ketamine treatment. BDI-II items
1-21 are shown on the x-axis. Hedges’ g effect size measures are plotted
along the y-axis (calculated with R package “effsize”). Positive values indicate
better item score improvements in responders than in non-responders.
Asterisks indicate significant differences between item score improvement of
responders and non-responders (Welch tests, p < 0.05, one-tailed,
uncorrected for multiple comparisons, test statistics are provided in
Supplementary Table S12).
DISCUSSION
In an open-label study, 26 participants with treatment-resistant
depression received 0.5 mg/kg ketamine via infusion. Mean
MADRS total score was 26.846 at baseline (range: 11–36,
n = 26) and dropped to 17.538 (range: 0–35, n = 26) 24 h
after treatment, and 18.64 (range: 0–34, n = 25) 7 days after
treatment. After 24 h nine of the 26 participants fulfilled
response criteria. Of these, eight remained responders after
7 days. Only one of 16 non-responders, according to MADRS
total score improvement after 24 h, fulfilled response criteria
after 7 days. Higher MADRS percent total score change from
baseline to 24 h after ketamine treatment corresponded to
higher BMI. Responders improved significantly more than non-
responders 24 h and 7 days after ketamine treatment in the
BDI-II items “Sadness” (item 1), “Self-Dislike” (item 7), and
“Self-Criticalness” (item 8).
Our results corroborate the study by Ballard et al. (2018).
They combined several studies in major depression and bipolar
depression and examined unique symptom clusters regarding
treatment response to ketamine. Ketamine’s strongest effects were
found on the clusters “negative cognition,” “depressed mood,”
“amotivation,” “anhedonia,” and “suicidal thoughts,” whereas
effects on the symptom clusters “tension,” “impaired sleep,” and
“reduced appetite” were less pronounced. The symptom cluster
“negative cognition” included eight BDI items: “Thoughts of
Failure,” “Guilt,” “Feelings of Punishment,” “Self-Criticalness,”
“Increased Crying,” “Worthlessness,” “Reduced Sexual Interest,”
and “Disappointment in Self.” The first seven of those items are
also present in BDI-II, which we used in our study. We observed
a better improvement in responders than non-responders in the
items “Self-Criticalness,” “Self-Dislike,” “Pessimistic Thoughts,”
“Increased Crying,” and “Worthlessness.” Overall, our findings
largely support an improvement in this symptom cluster.
Moreover, we found higher symptom improvement in the BDI-
II item “Sadness,” in line with the effects of ketamine on the
symptom cluster “depressed mood” reported by Ballard et al.
(2018) We also found a better improvement in responders
than non-responders in the BDI-II item “Suicidal Thoughts,”
consistent with the reported effect on the symptom cluster
“suicidal thoughts” (Ballard et al., 2018). Overall, our findings
are consistent with the reported effects of ketamine on symptom
clusters “negative cognition,” “depressed mood,” and “suicidal
thoughts” (Ballard et al., 2018).
Because our study period was longer (7 days versus 3 days), we
added to Ballard et al. (2018) report that most improvements in
negative self-schema were not only rapid but also sustained over
one week. In contrast to a previous meta-analysis on ketamine’s
effects on the BDI item “Suicidal Thoughts” (Wilkinson et al.,
2018), we found a significant improvement on this item in BDI-II,
after 24 h but not after 7 days.
In an integrative hypothesis of depression, Price and Duman
(2020) suggested that impaired neuroplasticity in depression
may be the neural substrate of rigid negative biases, including
negative appraisals of the self, which is a fundamental component
of the negative triad of depression. In his cognitive theory
of depression, (Beck, 1979) emphasized the central role of
negative self-schemata, a negative view of others, and negative
expectations about the future that significantly impair emotional
wellbeing and functioning. Taken together, our data suggest that
ketamine might positively influence dysfunctional self-schemata.
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Ketamine may have the potential to enhance cognitive-behavioral
psychotherapy in treatment-resistant depression (Hasler, 2019).
Consistent with previous meta-analyses (Han et al., 2016;
Kishimoto et al., 2016), we showed rapid and robust symptom
improvements following a single dose of ketamine as assessed
with MADRS. Our response rate of 34.6% was slightly lower
than previously reported, possibly because we defined treatment
resistance as non-response to at least three different treatments.
We found a high correlation of r = 0.832 (p < 0.001)
between symptom reductions after 24 h and after 7 days,
suggesting that antidepressant effects were sustained and not
identical with ketamine’s acute alterations of self-perception and
consciousness (Stocker et al., 2019). This finding indicates that
clinical response after 24 h is an important predictor of clinical
response after 7 days.
High BMI was associated with high MADRS total score
improvement after ketamine, which is consistent with previous
evidence that high BMI is one of the most replicable
predictors of the response to intravenous ketamine treatment
(Rong et al., 2018).
Several limitations of our study merit comments. First, the lack
of a placebo control condition is a major limitation. Whether the
observed decrease in depression scores after treatment reflects
the therapeutic action of ketamine, or unspecific placebo effects,
remains unclear (Kirsch, 2019). In addition, the lack of a control
group does not allow controlling for the effects of regression to
the mean on the average decrease of MADRS total scores we
observed. A second limitation of our study is multiple testing
without p-value correction. This increases the risk for false
positive findings and warrants caution when interpreting results.
On the other hand, consecutive conservative correction for 21
comparisons over three time points would have considerably
reduced statistical power and increased the risk for type II
“false negative” errors. Moreover, we found an item-response
profile after 24 h that remained stable after 7 days. Responders
improved more than non-responders on BDI-II items “Sadness,”
“Self-Dislike,” “Self-Criticalness,” and “Energy loss” 24 h and
7 days after ketamine treatment. Furthermore, the BDI-II item
profile we observed could be partly driven by different item
properties, such as different reliabilities, different item score
variances, and differences in item score correlations with baseline
and post-measurements. The use of percent score change from
baseline, difference scores, and the concept of responders and
non-responders have received critical evaluation (Vickers, 2001;
Snapinn and Jiang, 2007; Clifton and Clifton, 2019). Therefore,
results obtained with these measures should be regarded with
caution. The significant violations of normality assumption
we observed for several variables represent another limitation.
Skewed distributions might produce false positive findings in
parametric tests. To rule this out we supplemented analyses with
extensive non-parametric testing that corroborated most of the
results from parametric procedures.
Our results are based on the effects of ketamine that is a
racemic mixture containing equal amounts of the enantiomers
esketamine and arketamine. A dose of 0.25 mg/kg esketamine
had a similar short-term antidepressant effects and a similar
safety profile to 0.5 mg/kg ketamine, suggesting that esketamine
is the active enantiomer (Correia-Melo et al., 2020). However,
there is preliminary evidence that arketamine might provide
a more prolonged antidepressant response than esketamine
with less side effects, particularly with no dissociative and
hemodynamic effects. Since the clinical trials on esketamine and
arketamine did not include BDI as an outcome measure, more
research is needed to discuss the role of the two enantiomers
regarding their differential therapeutic effects on negative self-
schema in depression.
In summary, our findings suggest that ketamine may act
therapeutically in treatment resistant depression by improving
self-related cognitive biases. This is a potentially important
finding since negative self-schemata are at the core of cognitive
theories of depression (Beck, 1979) and associated with
impaired neuroplasticity in depression (Price and Duman,
2020). Independent replications in larger samples using placebo-
controlled study designs are needed to corroborate our findings.
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